Stockscreener 앱 받기
9.69
7.80%
-0.82
시간 외 거래:
9.69
Nurix Therapeutics Inc 주식(NRIX)의 최신 뉴스
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 4.2%What's Next? - MarketBeat
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given "Buy" Rating at HC Wainwright - MarketBeat
NEOS Investment Management LLC Takes $425,000 Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.9%Should You Sell? - MarketBeat
Nurix expands licensing deal with Sanofi - The Pharma Letter
Nurix Therapeutics (NRIX) Projected to Post Earnings on Wednesday - MarketBeat
Nurix Therapeutics (NRIX) Surges After Licensing Deal with Sanof - GuruFocus
Sanofi licensing deal boosts Nurix shares - MSN
Nurix stock rises after Sanofi licensing deal (NRIX:NASDAQ) - Seeking Alpha
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts - Benzinga
Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program - MarketScreener
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases - The Manila Times
Major Pharma Deal: Nurix's AI Platform Lands $480M Potential Sanofi Partnership - Stock Titan
Trend Tracker for (NRIX) - news.stocktradersdaily.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 12-Month LowWhat's Next? - MarketBeat
Nurix Therapeutics Inc (NASDAQ: NRIX) Drops -2.22%, Turning Investors Away - stocksregister.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Verastem (NASDAQ:VSTM) versus Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head Analysis - Defense World
Proficio Capital Partners LLC Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times
Nurix Therapeutics Announces Multiple Presentations At The American Association For Cancer Research (AACR) 2025 Annual Meeting - MarketScreener
Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight - Stock Titan
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 6.2%Here's What Happened - MarketBeat
Primecap Management Co. CA Sells 58,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Q3 Earnings Estimate for NRIX Issued By Leerink Partnrs - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Raised to "Hold" at Leerink Partnrs - MarketBeat
Victory Capital Management Inc. Buys 38,672 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Q1 Earnings Estimate for NRIX Issued By Leerink Partnrs - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.4%Should You Buy? - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely - simplywall.st
Nikko Asset Management Americas Inc. Acquires 236,620 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at Leerink Partners - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Upgraded at Leerink Partnrs - Defense World
Victory Capital Management Inc. Increases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 6.9%What's Next? - MarketBeat
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock - Benzinga
Nurix Therapeutics gets 'market perform' rating as Leerink starts coverage - TradingView
Leerink Partners Initiates Coverage of Nurix Therapeutics (NRIX) with Market Perform Recommendation - Nasdaq
Nurix Therapeutics' Bexobrutideg Gets Orphan Drug Designation For Waldenstrm Macroglobulinemia - Nasdaq
10.70%
자본화:
|
볼륨(24시간):